Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 47 PubMed citations indexed.
Epithalon (AEDG, Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal gland that stimulates telomerase (hTERT) expression and epigenetically modulates gene transcription by binding his
What the literature studies
Longevity Research
Evidence tier
Human Observational
Compounding record
Status not verified
Status not verified. Status not verified. Exact FDA substance context: FDA names Epitalon (Epithalon): Nomination withdrawn. The combination is not an independently verified FDA substance. Previously in Category 2; FDA still identifies potential significant safety risks for the named withdrawn substance. Withdrawal is not FDA approval or a determination of safety or compounding eligibility. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
The combination has no dedicated clinical evidence; individual compound studies come primarily from a single Russian research group (Khavinson), limiting independent replicat
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.